Market Research Future (MRFR) has published on the "Gabapentin Market”
The global Gabapentin market is accounted to register a CAGR of 5.90% during the forecast period (2023-2032) and is estimated to reach USD 3.7 billion by 2032.
Gabapentins are anti-convulsants, a kind of drug that helps persons with epilepsy control their seizures.The treatment of RLS and specific kinds of nerve discomfort includes the use of several gabapentin variants. The way gabapentin works is by changing the electrical simulation in the brain and activating neurotransmitters, which then cause nerve cells to communicate with one another.
The rise in neuropathic pain, seizures, and the use of the medicine as a pain reliever are all contributing factors to the expansion. Other factors include the growing elderly population, an increase in government activities, pharmaceutical companies' R&D spending, and rising product approvals.
Market Research Future (MRFR) has published a cooked research report on the “Global Gabapentin Market” that contains information from 2018 to 2032. The Gabapentin market is estimated to register a CAGR of 5.90% during the forecast period of 2023 to 2032.
The global gabapentin market has been segmented based dosage form, type, application and distribution channel.
On the basis of dosage form, the market is segmented into tablet, capsule, and oral solution. The capsule segment was attributed to holding the largest market share in 2022.
Based on type, the global gabapentin market has been segmented into generic and branded. The generic segment was expected to hold the largest market share in 2022.
Based on application, the global gabapentin market has been segmented into epilepsy, neuropathic pain, restless legs syndrome, and others. The epilepsy segment was expected to hold the largest market share in 2022.
Based on distribution channel, the global gabapentin market has been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. The hospital pharmacy segment was expected to hold the largest market share in 2022.
The global Gabapentin market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Gabapentin market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Gabapentin market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Gabapentin market comprises of Middle East, Africa, and Latin America.
In 2022, North America accounted for the largest revenue share in the global gabapentin market, and it is predicted that it would maintain this position during the forecast period. The dominance may be attributed to the high prevalence of neurological illnesses and diseases in the region that are marked by ongoing discomfort.
Moreover, in 2022, the European market greatly increased overall revenue. The increased demand for anti-convulsants, government initiatives, and product approvals are likely to boost the regional market.
Additionally, the Asia-Pacific region is expected to have considerable growth over the course of the projection period due to growing awareness of gabapentin's advantages over opioids and rising healthcare spending in developing countries like China and India.
Furthermore, the rest of the world's Gabapentin market is divided into the Middle East, Africa, and Latin America. The gabapentin market in Latin America and the Middle East & Africa (MEA) region is expected to witness significant growth in the coming years. Gabapentin is a medication used to treat epilepsy and neuropathic pain.
MRFR recognizes the following companies as the key players in the global Gabapentin market— Zydus Pharmaceuticals, Inc, Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Ascend Laboratories, LLC, Apotex Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Amneal Pharmaceuticals LLC., Cipla USA, Inc., BP Pharmaceuticals Laboratories Company, Assertio Holdings, Inc., Arbor Pharmaceuticals, Inc., Pfizer Inc.
Key Findings of the Study